sglt2 inhibitor glp 1 agonist combination Frontiers Effect of combination treatment with

Cell Commun Signal (2022) 20(1):166

How GLP-1 Drugs Differ Although they share a receptor target, GLP-1 medications differ in several clinically meaningful ways

Research published in The Lancet examining GLP-1 receptor agonist eligibility across 99 countries found that eligibility varies dramatically based on which BMI thresholds are used

doi: 10.1210/endrev/bnz009 5 MussoGCassaderMRosinaFGambinoR

Overall, results from the cardiovascular outcomes trials (CVOTs) completed for all marketed GLP-1 RAs in type 2 diabetes support a benefit in HF specifically in addition to the approved use in broad CVD risk reduction in people with type 2 diabetes (Sattar et al., 2021)